Bacheler L, Ackerman K, Sheridan P, Pachl C, Swanson K, Winslow D; International Conference on AIDS.
Int Conf AIDS. 1993 Jun 6-11; 9: 550 (abstract no. PO-B41-2488).
DuPont Merck Pharmaceutical Company, Wilmington, DE 19880-0400.
Eight patients enrolled in the CPCRA NuCombo Protocol 007 were monitored for CD4+ cell counts, plasma p24 antigen, and plasma HIV RNA. This protocol is a randomized, comparative trial of ZDV vs. ZDV plus ddl vs. ZDV plus ddC in HIV infected patients with CD4+ counts of < 200 cells per mm3. Filtered plasma samples were collected at the time of entry into the trial, and for an additional 4-8 months. Free p24 antigen levels in plasma were determined using a commercial ELISA kit (DuPont). Viral RNA levels in plasma were quantified in a HIV RNA assay using branched DNA (bDNA) signal amplification technology (Chiron). All patients were positive for HIV RNA, while free p24 antigen was detected in 4 out of 8 patients. The effect of filtering plasma samples through a 0.8 mu filter to remove platelets on the recovery of HIV RNA was studied. In specimens ranging from 1.5 x 10(4) to 3.6 x 10(5) HIV RNA equivalents/ml plasma, the average difference between filtered and unfiltered plasma was 13%, indicating that filtered plasma can be used in the bDNA assay. Results of this longitudinal survey in eight patients on anti-retroviral therapy will be presented.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Antiviral Agents
- CD4 Lymphocyte Count
- HIV
- HIV Antigens
- HIV Core Protein p24
- HIV Infections
- HIV Seropositivity
- Humans
- Immunologic Techniques
- Longitudinal Studies
- RNA, Viral
- Viremia
- Zidovudine
- immunology
- organization & administration
Other ID:
UI: 102205520
From Meeting Abstracts